**Supplementary Table 1. Newcastle-Ottawa scale score quality assessment of the included case-control studies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year** | **Selection (4 points)** | **Comparability (2 points)** | **Exposure (3 points)** | **Score (up to 9 points)** |
| Shen 2020[26] | 4 | 2 | 3 | 9 |
| Ramirez 2017[29] | 4 | 1 | 0 | 5 |
| Kim 2017[31] | 4 | 1 | 2 | 7 |
| Yang 2016[32] | 4 | 1 | 2 | 7 |
| Chiu 2010[34] | 4 | 1 | 1 | 6 |

**References**

26. Shen Y, Risch H, Lu L, Ma X, Irwin ML, Lim JK, *et al*. Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study. Cancer Causes Control 2020;31(4):321-332. doi: 10.1007/s10552-020-01277-1. PMID: 32060838.

29. Ramirez AG, Muñoz E, Parma DL, Michalek JE, Holden AEC, Phillips TD, *et al*. Lifestyle and Clinical Correlates of Hepatocellular Carcinoma in South Texas: A Matched Case-control Study. Clin Gastroenterol Hepatol 2017;15(8):1311-1312. doi: 10.1016/j.cgh.2017.03.022. PMID: 28344065.

31. Kim G, Jang SY, Han E, Lee YH, Park SY, Nam CM, *et al*. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study. Int J Cancer 2017;140(4):798-806. doi: 10.1002/ijc.30506. PMID: 27861855.

32. Yang B, Petrick JL, Chen J, Hagberg KW, Sahasrabuddhe VV, Graubard BI, *et al*. Associations of NSAID and paracetamol use with risk of primary liver cancer in the Clinical Practice Research Datalink. Cancer Epidemiol 2016;43:105-111. doi: 10.1016/j.canep.2016.06.009. PMID: 27420633.

34. Chiu HF, Ho SC, Chen CC, Yang CY. Statin Use and the Risk of Liver Cancer: A Population-Based Case–Control Study. Am J Gastroenterol 2011;106(5):894-898. doi: 10.1038/ajg.2010.475. PMID: 21157439.